605 related articles for article (PubMed ID: 23013949)
21. Conversion to everolimus in liver transplant patients with renal dysfunction.
Pérez T; Segovia R; Castro L; Roblero JP; Estela R
Transplant Proc; 2011; 43(6):2307-10. PubMed ID: 21839260
[TBL] [Abstract][Full Text] [Related]
22. Results of 4-year analysis of conversion from calcineurin inhibitors to mTOR inhibitors in renal transplant patients: single-center experience.
Sert M; Celik A; Kural K; Ersan S; Ataca P; Atila K; Cavdar C; Sifil A; Bora S; Gulay H; Camsari T
Ren Fail; 2011; 33(8):789-94. PubMed ID: 21787153
[TBL] [Abstract][Full Text] [Related]
23. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
[TBL] [Abstract][Full Text] [Related]
24. Everolimus in clinical practice in long-term liver transplantation: an observational study.
Casanovas T; Argudo A; Peña-Cala MC
Transplant Proc; 2011; 43(6):2216-9. PubMed ID: 21839237
[TBL] [Abstract][Full Text] [Related]
25. Monotherapy rapamycin in renal transplant recipients with lymphoma successfully treated with rituximab.
Alexandru S; Gonzalez E; Grande C; Hernandez A; Morales E; Praga M; Andres A; Morales JM
Transplant Proc; 2009; 41(6):2435-7. PubMed ID: 19715944
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-2 receptor antibody reduces rejection rates and graft loss in live-donor kidney transplant recipients.
Lim WH; Chang SH; Chadban SJ; Campbell SB; Dent H; Russ GR; McDonald SP
Transplantation; 2009 Nov; 88(10):1208-13. PubMed ID: 19935375
[TBL] [Abstract][Full Text] [Related]
27. Sirolimus monotherapy as maintenance immunosuppression: a multicenter experience.
Pinto JR; Arellano Torres EM; Franco A; Morales JM; Ruiz JC; Diekmann F; Alperovich G; Campistol JM
Transpl Int; 2010 Mar; 23(3):307-12. PubMed ID: 19843293
[TBL] [Abstract][Full Text] [Related]
28. Annual trends and triple therapy--1991-2000.
Nishikawa K; Terasaki PI
Clin Transpl; 2001; ():247-69. PubMed ID: 12211788
[TBL] [Abstract][Full Text] [Related]
29. Alemtuzumab induction with tacrolimus monotherapy in 25 pediatric renal transplant recipients.
Sung J; Barry JM; Jenkins R; Rozansky D; Iragorri S; Conlin M; Al-Uzri A
Pediatr Transplant; 2013 Dec; 17(8):718-25. PubMed ID: 24164824
[TBL] [Abstract][Full Text] [Related]
30. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
31. Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus.
Casas-Melley AT; Falkenstein KP; Flynn LM; Ziegler VL; Dunn SP
Pediatr Transplant; 2004 Aug; 8(4):362-6. PubMed ID: 15265163
[TBL] [Abstract][Full Text] [Related]
32. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency.
Peddi VR; Jensik S; Pescovitz M; Pirsch J; Adler SH; Thistlethwaite JR; Vincenti F; Cohen DJ
Clin Transplant; 2005 Feb; 19(1):130-6. PubMed ID: 15659146
[TBL] [Abstract][Full Text] [Related]
33. Clinical everolimus experience in pediatric renal transplant patients.
Dincel N; Bulut IK; Sezer TÖ; Mir S; Hoşcoşkun C
Transplant Proc; 2013 Apr; 45(3):913-6. PubMed ID: 23622585
[TBL] [Abstract][Full Text] [Related]
34. Treatment with everolimus is associated with a procoagulant state.
Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ
Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
[TBL] [Abstract][Full Text] [Related]
35. Renal function preservation with the mTOR inhibitor, Everolimus, after lung transplant.
Schneer S; Kramer MR; Fox B; Rusanov V; Fruchter O; Rosengarten D; Bakal I; Medalion B; Raviv Y
Clin Transplant; 2014 Jun; 28(6):662-8. PubMed ID: 24738962
[TBL] [Abstract][Full Text] [Related]
36. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
Diekmann F; Andrés A; Oppenheimer F
Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
[TBL] [Abstract][Full Text] [Related]
37. Conversion to sirolimus in renal transplant recipients: a single-center experience.
Yelken B; Caliskan Y; Ozkan O; Gorgulu N; Yazici H; Turkmen A; Sever MS
Artif Organs; 2010 Aug; 34(8):E230-7. PubMed ID: 20618227
[TBL] [Abstract][Full Text] [Related]
38. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
[TBL] [Abstract][Full Text] [Related]
39. Calcineurin inhibitor conversion to rapamycin can improve graft function in living donor kidney transplantation with older donors.
Chen GD; Liu XC; Shi L; Qiu J; Wang CX; Fei JG; Li J; Huang G; Chen LZ
Transplant Proc; 2013 May; 45(4):1648-50. PubMed ID: 23726640
[TBL] [Abstract][Full Text] [Related]
40. Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
Luna E; Cerezo I; Macias R; Villa J; Martinez C; Cubero J; Martinez R; Ferreira F; García C
Transplant Proc; 2011; 43(6):2187-90. PubMed ID: 21839229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
